Mostrar el registro sencillo del ítem

dc.contributor.authorCorbalan, R.
dc.contributor.authorBassand, J. P.
dc.contributor.authorIllingworth, L.
dc.contributor.authorAmbrosio, G.
dc.contributor.authorCamm, A. J.
dc.contributor.authorFitzmaurice, D. A.
dc.contributor.authorFox, K. A. A.
dc.contributor.authorGoldhaber, S. Z.
dc.contributor.authorGoto, S.
dc.contributor.authorHaas, S.
dc.contributor.authorKayani, G.
dc.contributor.authorMantovani, L. G.
dc.contributor.authorMisselwitz, F.
dc.contributor.authorPieper, K. S.
dc.contributor.authorTurpie, A. G. G.
dc.contributor.authorVerheugt, F. W. A.
dc.contributor.authorKakkar, A. K.
dc.contributor.authorGrigorian Shamagian, Lilian
dc.contributor.authorMazón Ramos, María Pilar 
dc.contributor.authorGarcía Millán, Vanesa
dc.contributor.authorGonzález Juanatey, José Ramón 
dc.contributor.authorSeoane Blanco, Ana
dc.contributor.authorMoure González, María 
dc.date.accessioned2021-11-02T11:35:43Z
dc.date.available2021-11-02T11:35:43Z
dc.date.issued2019
dc.identifier.issn2380-6583
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31066873
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15632
dc.description.abstractImportance: Congestive heart failure (CHF) is commonly associated with nonvalvular atrial fibrillation (AF), and their combination may affect treatment strategies and outcomes. Objective: To assess the treatment strategies and 1-year clinical outcomes of antithrombotic and CHF therapies for patients with newly diagnosed AF with concomitant CHF stratified by etiology (ischemic cardiomyopathy [ICM] vs nonischemic cardiomyopathy [NICM]). Design, Setting, and Participants: The GARFIELD-AF registry is a prospective, noninterventional registry. A total of 52014 patients with AF were enrolled between March 2010 and August 2016. A total of 11738 patients 18 years and older with newly diagnosed AF (</=6 weeks' duration) and at least 1 investigator-determined stroke risk factor were included. Data were analyzed from December 2017 to September 2018. Exposures: One-year follow-up rates of death, stroke/systemic embolism, and major bleeding were assessed. Main Outcomes and Measures: Event rates per 100 person-years were estimated from the Poisson model and Cox hazard ratios (HRs) and 95% confidence intervals. Results: The median age of the population was 71.0 years, 22987 of 52013 were women (44.2%) and 31958 of 52014 were white (61.4%). Of 11738 patients with CHF, 4717 (40.2%) had ICM and 7021 (59.8%) had NICM. Prescription of oral anticoagulant and antiplatelet drugs was not balanced between groups. Oral anticoagulants with or without antiplatelet drugs were used in 2753 patients with ICM (60.1%) and 5082 patients with NICM (73.7%). Antiplatelets were prescribed alone in 1576 patients with ICM (34.4%) and 1071 patients with NICM (15.5%). Compared with patients with NICM, use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (72.6% [3439] vs 60.3% [4236]) and of beta blockers (63.3% [2988] vs 53.2% [3737]) was higher in patients with ICM. Rates of all-cause and cardiovascular death per 100 patient-years were significantly higher in the ICM group (all-cause death: ICM, 10.2; 95% CI, 9.2-11.1; NICM, 7.0; 95% CI, 6.4-7.6; cardiovascular death: ICM, 5.1; 95% CI, 4.5-5.9; NICM, 2.9; 95% CI, 2.5-3.4). Stroke/systemic embolism rates tended to be higher in ICM groups compared with NICM groups (ICM, 2.0; 95% CI, 1.6-2.5; NICM, 1.5; 95% CI, 1.3-1.9). Major bleeding rates were significantly higher in the ICM group (1.1; 95% CI, 0.8-1.4) compared with the NICM group (0.7; 95% CI, 0.5-0.9). Conclusions and Relevance: Patients with ICM received oral anticoagulants with or without antiplatelet drugs less frequently and antiplatelets alone more frequently than patients with NICM, but they received angiotensin-converting enzyme inhibitors/angiotensin receptor blockers more often than patients with NICM. All-cause and cardiovascular death rates were higher in patients with ICM than patients with NICM. Trial Registration: ClinicalTrials.gov Identifier: NCT01090362.
dc.subject.meshProportional Hazards Models*
dc.subject.meshAdrenergic beta-Antagonists*
dc.subject.meshAngiotensin-Converting Enzyme Inhibitors*
dc.subject.meshDigoxin*
dc.subject.meshAnticoagulants*
dc.subject.meshCardiomyopathies*
dc.subject.meshHumans*
dc.subject.meshRegistries*
dc.subject.meshAtrial Fibrillation*
dc.subject.meshCardiotonic Agents*
dc.subject.meshStroke Volume*
dc.subject.meshAngiotensin Receptor Antagonists*
dc.subject.meshCardiovascular Diseases*
dc.subject.meshPractice Guidelines as Topic*
dc.subject.meshAged*
dc.subject.meshCohort Studies*
dc.titleAnalysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation A Report From the GARFIELD-AF Registry
dc.typeArtigoes
dc.contributor.authorcorpGARFIELD-AF Investigators
dc.authorsophosGonzález Juanatey, José Ramón
dc.authorsophosGrigorian Shamagian, Lilian
dc.authorsophosSeoane Blanco, Ana
dc.authorsophosMoure González, María
dc.authorsophosMazón Ramos, María Pilar
dc.authorsophosGarcía Millán, Vanesa
dc.identifier.doi10.1001/jamacardio.2018.4729
dc.identifier.pmid31066873
dc.identifier.sophos31173
dc.issue.number6
dc.journal.titleJournal of the American Medical Association cardiology
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Cardioloxía
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)
dc.page.initial526es
dc.page.final548es
dc.relation.publisherversionhttps://jamanetwork.com/journals/jamacardiology/articlepdf/2732488/jamacardiology_corbalan_2019_oi_180075.pdf
dc.subject.decsenfermedades cardiovasculares*
dc.subject.decsmiocardiopatías*
dc.subject.decscardiotónicos*
dc.subject.decsinhibidores de la enzima covertidora de angiotensina*
dc.subject.decsanticoagulantes*
dc.subject.decsguías de práctica clínica como asunto*
dc.subject.decsdigoxina*
dc.subject.decssistema de registros*
dc.subject.decsantagonistas adrenérgicos beta*
dc.subject.decsanciano*
dc.subject.decsvolumen sistólico*
dc.subject.decshumanos*
dc.subject.decsantagonistas de receptores de angiotensina*
dc.subject.decsfibrilación atrial*
dc.subject.decsestudios de cohortes*
dc.subject.decsmodelos de riesgos proporcionales*
dc.subject.keywordCHUS
dc.subject.keywordIDIS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number4


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem